September 18, 2025MedicinaOpen Access

Improving MDS Risk Assessment: The Role of Monocytopenia and Lymphocytopenia Beyond IPSS-R

View Full Paper

Ask AI

Bookmark

Authors

Discussion

Retrospective analysis highlights monocytopenia and lymphocytopenia's impact on overall survival in MDS patients, suggesting new prognostic markers.

Patients with monocytopenia had median overall survival of 20 months compared to 60 months for those without, indicating severe impact.
Lymphocytopenia was associated with an overall survival of 17 months versus 29 months without, reinforcing its significance.
Independent prognostic factors identified include IPSS-R, monocytopenia, and lymphocytopenia, indicating stronger risk stratification capabilities.
Findings suggest implementing monocytopenia and lymphocytopenia into existing models may enhance risk assessment for MDS patients.

Virijević et al. (2025) studied this question.

View Full Paper

Ask AI

Bookmark

Retrospective analysis highlights monocytopenia and lymphocytopenia's impact on overall survival in MDS patients, suggesting new prognostic markers.